10.03.14
Newtown, Pa.-based Helius Medical Technologies Inc. has been given investigational testing authorization from Health Canada for its PoNS device. Helius intends to initiate a study of the PoNS device in the treatment of symptoms associated with multiple sclerosis (MS). Upon institutional review board approval, the study is scheduled to commence at the Montreal Neurological Institute. The PoNS, an investigational medical device that induces neuromodulation by stimulating the cranial nerves found in the tongue, is initially being studied for the treatment of balance disorder symptoms caused by traumatic brain injury (TBI) and MS.
“Part of the business strategy at Helius is to test the PoNS device against neurological symptoms of varying etiologies including trauma (as in TBI), progressive disease (as exampled with MS) and potentially a cognitive disorder (such as in Alzheimer’s disease),” said CEO Philippe Deschamps. “We are excited to be working with the Montreal Neurological Institute, a world class center for MS research, as we continue to execute on this strategy and direct resources towards this debilitating disease.”
Helius makes non-invasive technology to treat neurological conditions.
“Part of the business strategy at Helius is to test the PoNS device against neurological symptoms of varying etiologies including trauma (as in TBI), progressive disease (as exampled with MS) and potentially a cognitive disorder (such as in Alzheimer’s disease),” said CEO Philippe Deschamps. “We are excited to be working with the Montreal Neurological Institute, a world class center for MS research, as we continue to execute on this strategy and direct resources towards this debilitating disease.”
Helius makes non-invasive technology to treat neurological conditions.